Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 15/20 | 0.58 |
| ▸ | STK17B | O94768 | 10/20 | 0.58 |
| ▸ | BCL6 | P41182 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411447 | 0.88 | STK17A (0.66) | STK17ASTK17B | |
| SCHEMBL5402321 | 0.85 | STK17A (0.55) | STK17ASTK17BHDAC3HDAC1HDAC2 | |
| SCHEMBL5420012 | 0.84 | STK17A (0.58) | STK17ASTK17BSLC2A1 | |
| SCHEMBL5405290 | 0.84 | STK17A (0.58) | STK17ASTK17BSLC2A1 | |
| SCHEMBL5415243 | 0.83 | STK17A (0.62) | STK17ASTK17B | |
| SCHEMBL5422291 | 0.82 | STK17A (0.52) | STK17ASTK17BBCL6HDAC3HDAC1 | |
| SCHEMBL5414085 | 0.80 | STK17A (0.56) | STK17ASTK17BBCL6BRD4 | |
| SCHEMBL5518128 | 0.79 | CDK4 (0.45) | STK17ASTK17B | |
| SCHEMBL303236 | 0.78 | STK17A (0.62) | STK17ASTK17BBCL6BRD4 | |
| SCHEMBL10998426 | 0.77 | HDAC3 (0.51) | STK17ASTK17BHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166599-B2 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | disclosed |
| US-20050090486-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-04-28 | — | — | US | disclosed |
| US-20030134838-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134838-A1 | Trisubstituted pyrimidines | APP, PSEN1, BACE1 | STK17A 3301/4885STK17B 3455/4885BCL6 3532/4885 |
| US-20050090486-A1 | Trisubstituted pyrimidines | APP, BACE1, PSEN1 | STK17A 3456/4885STK17B 3502/4885BCL6 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.